RT Journal
A1 Whitley RJ
T1 INcomplete financial disclosures in an editorial, clinical crossroads, and reply letter related to herpes zoster
JF JAMA
JO JAMA
YR 2010
FD February 24
VO 303
IS 8
SP 733
OP 734
DO 10.1001/jama.2010.109
UL http://dx.doi.org/10.1001/jama.2010.109
AB 
To the Editor:  I would like to report incomplete financial disclosures related to an Editorial,1 a Clinical Crossroads article,2 and a subsequent reply to a letter to the editor3 published in JAMA. This resulted from my misinterpretation of JAMA requirements for reporting conflicts of interest. As I noted previously,1- 3 I am on the board of directors of Gilead Sciences and a consultant for Chimerix; I receive compensation and stock from both companies. Neither company is involved in the development of drugs to treat herpesvirus infections. However, I did not report 3 financial disclosure issues.